Indoco Remedies Ltd
NSE:INDOCO

Watchlist Manager
Indoco Remedies Ltd Logo
Indoco Remedies Ltd
NSE:INDOCO
Watchlist
Price: 210.96 INR -2.43% Market Closed
Market Cap: 19.4B INR
Section:
 

Relative Value

The Relative Value of one INDOCO stock under the Base Case scenario is 545.41 INR. Compared to the current market price of 210.96 INR, Indoco Remedies Ltd is Undervalued by 61%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

INDOCO Relative Value
Base Case
545.41 INR
Undervaluation 61%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

1.1
P/S
P/S
Price to Sales
1.1
vs History
96
vs Industry
64
Median 3Y
1.7
Median 5Y
2.1
Industry
2.7
Forward
1.1
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
15
Median 3Y
22.5
Median 5Y
26.5
Industry
21.6
Forward
-75.8
More Details
13.8
P/OCF
P/OCF
Price to OCF
13.8
vs History
84
vs Industry
36
Median 3Y
19
Median 5Y
19.6
Industry
16.9
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
28
Median 3Y
49
Median 5Y
42.7
Industry
22.9
More Details
2
P/B
P/B
Price to Book Value
2
vs History
96
vs Industry
36
Median 3Y
2.8
Median 5Y
3.1
Industry
2.3
More Details
1.4
EV/S
EV/S
Enterprise Value to Sales
1.4
vs History
96
vs Industry
58
Median 3Y
1.9
Median 5Y
2.2
Industry
3
Forward
1.3
More Details
2
EV/GP
EV/GP
Enterprise Value to Gross Profit
2
vs History
96
vs Industry
67
Median 3Y
2.8
Median 5Y
3.1
Industry
5.6
More Details
33.7
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
33.7
vs History
11
vs Industry
20
Median 3Y
16.4
Median 5Y
15.4
Industry
13.4
Forward
14.2
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
5
Median 3Y
19.3
Median 5Y
19.1
Industry
16.7
Forward
25.3
More Details
17.2
EV/OCF
EV/OCF
Enterprise Value to OCF
17.2
vs History
79
vs Industry
33
Median 3Y
21.4
Median 5Y
21.4
Industry
16.1
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
2
Median 3Y
-12.9
Median 5Y
-11.3
Industry
18.9
More Details
1.1
EV/IC
EV/IC
Enterprise Value to IC
1.1
vs History
96
vs Industry
48
Median 3Y
1.7
Median 5Y
2.1
Industry
2
More Details

Multiples Across Competitors

INDOCO Competitors Multiples
Indoco Remedies Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Indoco Remedies Ltd
NSE:INDOCO
19.5B INR 1.1 -17.6 33.7 -50.7
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.1 55.1 37 39.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
525.9B USD 5.7 20.9 17.1 22.2
CH
Roche Holding AG
SIX:ROG
275.8B CHF 4.5 29.2 12.4 14.5
UK
AstraZeneca PLC
LSE:AZN
223.4B GBP 5.2 31.9 109.3 159.9
CH
Novartis AG
SIX:NOVN
223.8B CHF 5 19.4 12.3 15.9
US
Merck & Co Inc
NYSE:MRK
276.1B USD 4.3 14.5 10.3 12.2
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.3 16 11.1 13
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
145.4B USD 2.3 14.8 7.5 10.3
P/E Multiple
Earnings Growth PEG
IN
Indoco Remedies Ltd
NSE:INDOCO
Average P/E: 25.3
Negative Multiple: -17.6 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
55.1
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20.9
29%
0.7
CH
Roche Holding AG
SIX:ROG
29.2
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.9
37%
0.9
CH
Novartis AG
SIX:NOVN
19.4
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.5
15%
1
DK
Novo Nordisk A/S
CSE:NOVO B
16
3%
5.3
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.8
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
Indoco Remedies Ltd
NSE:INDOCO
Average EV/EBITDA: 403.2
33.7
54%
0.6
US
Eli Lilly and Co
NYSE:LLY
37
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
17.1
9%
1.9
CH
Roche Holding AG
SIX:ROG
12.4
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
109.3
10%
10.9
CH
Novartis AG
SIX:NOVN
12.3
6%
2
US
Merck & Co Inc
NYSE:MRK
10.3
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
11.1
1%
11.1
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
Indoco Remedies Ltd
NSE:INDOCO
Average EV/EBIT: 1 883.9
Negative Multiple: -50.7 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.6
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
22.2
15%
1.5
CH
Roche Holding AG
SIX:ROG
14.5
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
159.9
23%
7
CH
Novartis AG
SIX:NOVN
15.9
12%
1.3
US
Merck & Co Inc
NYSE:MRK
12.2
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
13
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
7%
1.5

See Also

Summary
INDOCO intrinsic value, competitors valuation, and company profile.
DCF Valuation
INDOCO stock valuation using Discount Cash Flow valuation method.
Relative Valuation
INDOCO stock valuation using valuation multiples.
Wall Street Estimates
INDOCO price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
INDOCO stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 309,700+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.